Table 3.
Univariate and multivariate analysis of factors associated with achievement of low disease activity (DAS28ESR <3.2) among patients with moderate disease activity (n = 493).
| Variable | Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 95% CI | p | 95% CI | p | ||||||
| n | OR | Lower | Upper | OR | Lower | Upper | |||
| Sex, male | 493 | 2.15 | 1.32 | 3.51 | 0.002 | 2.13 | 1.30 | 3.99 | 0.004 |
| Age | 493 | 0.99 | 0.98 | 1.01 | 0.98 | 1.002 | 0.98 | 1.02 | 0.81 |
| Working status, <67 years | 444 | 1.59 | 1.02 | 2.48 | 0.041 | ||||
| bDMARD use | |||||||||
| 1st line versus no bDMARD | 493 | 0.86 | 0.55 | 1.34 | 0.50 | ||||
| ⩾2nd line versus no bDMARD | 0.60 | 0.38 | 0.93 | 0.22 | |||||
| HAQ score at first evaluation | 433 | 0.7 | 0.49 | 1.001 | 0.051 | ||||
| Co-morbidity index, RDCI | 493 | 0.87 | 0.75 | 1.009 | 0.065 | 0.81 | 0.68 | 0.97 | 0.024 |
| History of serious infection | 493 | 0.49 | 0.27 | 0.89 | 0.018 | ||||
| “Lower” versus “Higher” MDA status | 493 | 2.03 | 1.40 | 2.95 | <0.001 | 1.93 | 1.27 | 2.94 | 0.002 |
Number of patients included in the final model = 407. Variables with statistically significant differences (p < 0.05) between groups by multivariate analysis are shown in bold. “Higher” moderate disease activity (MDA) status = DAS28ESR, 4.2–5.1; “Lower” MDA status = DAS28ESR: 3.2–4.1.
bDMARD, biologic disease-modifying anti-rheumatic drug; CI, confidence interval; DAS28, Disease Activity Score using 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; OR, odds ratio; RDCI, Rheumatic Disease Comorbidity Index.